--(BUSINESS WIRE)--#ASCO--PanGIA Biotech, a company advancing urine-based ... using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled ...

April 30, 2025--(BUSINESS WIRE)--PanGIA Biotech, a company advancing urine-based ... using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and ...

PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc ...

These companies had the highest dollar trading volume of any Biotech stocks within the last several days. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 ...

- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - RBT-1 is a single ...

In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior ...